Evidence-Based Approach for the Management of Cerebral Metastases from Lung Adenocarcinoma

Part of the Tumors of the Central Nervous System book series (TCNS, volume 14)

Abstract

Adenocarcinoma is the most common histologic subtype of lung cancer in most countries, accounting for almost half of all lung cancers. A considerable proportion of non-small-cell lung cancer [NSCLC] patients will develop central nervous system [CNS] metastases throughout the course of their disease and these manifestations cause significant morbidity and mortality. Thus, aggressive management of cerebral metastases is vital to preventing death from neurological causes and prolonging functional independence. This chapter focuses on current knowledge of pathology, imaging and management of brain metastases from lung adenocarcinoma and outlines a practical approach for the management of cerebral metastases.

Keywords

Brain Metastasis Lung Adenocarcinoma Anaplastic Lymphoma Kinase Recursive Partitioning Analysis Cerebral Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abrey LE, Olson JD, Raizer JJ, Mack M, Rodavitch A, Boutros DY, Malkin MG (2001) A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53(3):259–265CrossRefPubMedGoogle Scholar
  2. Akeson P, Nordstrom CH, Holtas S (1997) Time-dependency in brain lesion enhancement with gadodiamide injection. Acta Radiol 38(1):19–24CrossRefPubMedGoogle Scholar
  3. Al-Okaili RN, Krejza J, Wang S, Woo JH, Melhem ER (2006) Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 26(Suppl 1):S173–S189CrossRefPubMedGoogle Scholar
  4. Bailon O, Chouahnia K, Augier A, Bouillet T, Billot S, Coman I, Ursu R, Belin C, Zelek L, Des Guetz G, Levy C, Carpentier AF, Morere JF (2012) Upfront association of carboplatin plus pemetrexed in patients with brain metastases of lung adenocarcinoma. Neuro Oncol 14(4):491–495PubMedCentralCrossRefPubMedGoogle Scholar
  5. Baleriaux D, Colosimo C, Ruscalleda J, Korves M, Schneider G, Bohndorf K, Bongartz G, van Buchem MA, Reiser M, Sartor K, Bourne MW, Parizel PM, Cherryman GR, Salerio I, La Noce A, Pirovano G, Kirchin MA, Spinazzi A (2002) Magnetic resonance imaging of metastatic disease to the brain with gadobenate dimeglumine. Neuroradiology 44(3):191–203CrossRefPubMedGoogle Scholar
  6. Ba-Ssalamah A, Nobauer-Huhmann IM, Pinker K, Schibany N, Prokesch R, Mehrain S, Mlynarik V, Fog A, Heimberger K, Trattnig S (2003) Effect of contrast dose and field strength in the magnetic resonance detection of brain metastases. Invest Radiol 38(7):415–422PubMedGoogle Scholar
  7. Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M, Talamini R, Santoro A, Bartolotti M, Murgia V, Berretta M, Tirelli U (2010) Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer 68(2):264–268CrossRefPubMedGoogle Scholar
  8. Bindal RK, Sawaya R, Leavens ME, Lee JJ (1993) Surgical treatment of multiple brain metastases. J Neurosurg 79(2):210–216CrossRefPubMedGoogle Scholar
  9. Brooks DJ (2005) Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx 2(2):226–236PubMedCentralCrossRefPubMedGoogle Scholar
  10. Bukte Y, Paksoy Y, Genc E, Uca AU (2005) Role of diffusion-weighted MR in differential diagnosis of intracranial cystic lesions. Clin Radiol 60(3):375–383CrossRefPubMedGoogle Scholar
  11. Carrier DA, Mawad ME, Kirkpatrick JB, Schmid MF (1994) Metastatic adenocarcinoma to the brain: MR with pathologic correlation. AJNR Am J Neuroradiol 15(1):155–159PubMedGoogle Scholar
  12. Chua D, Krzakowski M, Chouaid C, Pallotta MG, Martinez JI, Gottfried M, Curran W, Throuvalas N (2010) Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non- small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer 11(3):176–181CrossRefPubMedGoogle Scholar
  13. Colosimo C, Ruscalleda J, Korves M, La Ferla R, Wool C, Pianezzola P, Kirchin MA (2001) Detection of intracranial metastases: a multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage. Invest Radiol 36(2):72–81CrossRefPubMedGoogle Scholar
  14. Dziadziuszko R, Ardizzoni A, Postmus PE, Smit EF, Price A, Debruyne C, Legrand C, Giaccone G, Group ELC (2003) Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 39(9):1271–1276CrossRefPubMedGoogle Scholar
  15. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751CrossRefPubMedGoogle Scholar
  16. Gore EM, Bae K, Wong SJ, Sun A, Bonner JA, Schild SE, Gaspar LE, Bogart JA, Werner-Wasik M, Choy H (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29(3):272–278PubMedCentralCrossRefPubMedGoogle Scholar
  17. Guo S, Reddy CA, Chao ST, Suh JH, Barnett GH, Vogelbaum MA, Videtic GM (2012) Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases. Lung Cancer 77(2):389–393CrossRefPubMedGoogle Scholar
  18. Hakyemez B, Erdogan C, Bolca N, Yildirim N, Gokalp G, Parlak M (2006) Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. J Magn Reson Imaging 24(4):817–824CrossRefPubMedGoogle Scholar
  19. Hatiboglu MA, Wildrick DM, Sawaya R (2013) The role of surgical resection in patients with brain metastases. Ecancermedicalscience 7:308PubMedCentralPubMedGoogle Scholar
  20. Hayashida Y, Hirai T, Morishita S, Kitajima M, Murakami R, Korogi Y, Makino K, Nakamura H, Ikushima I, Yamura M, Kochi M, Kuratsu JI, Yamashita Y (2006) Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity. AJNR Am J Neuroradiol 27(7):1419–1425PubMedGoogle Scholar
  21. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90CrossRefPubMedGoogle Scholar
  22. Knauth M, Forsting M, Hartmann M, Heiland S, Balzer T, Sartor K (1996) MR enhancement of brain lesions: increased contrast dose compared with magnetization transfer. AJNR Am J Neuroradiol 17(10):1853–1859PubMedGoogle Scholar
  23. Kojima Y, Kuwana N, Noji M, Tosa J (1994) Differentiation of malignant glioma and metastatic brain tumor by thallium-201 single photon emission computed tomography. Neurol Med Chir (Tokyo) 34(9):588–592CrossRefGoogle Scholar
  24. Kruger S, Mottaghy FM, Buck AK, Maschke S, Kley H, Frechen D, Wibmer T, Reske SN, Pauls S (2011) Brain metastasis in lung cancer. Comparison of cerebral MRI and 18F-FDG-PET/CT for diagnosis in the initial staging. Nuklearmedizin 50(3):101–106CrossRefPubMedGoogle Scholar
  25. Lee DH, Han JY, Kim HT, Yoon SJ, Pyo HR, Cho KH, Shin SH, Yoo H, Lee SH, Lee JS (2008) Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer 113(1):143–149CrossRefPubMedGoogle Scholar
  26. Nathoo N, Chahlavi A, Barnett GH, Toms SA (2005) Pathobiology of brain metastases. J Clin Pathol 58(3):237–242PubMedCentralCrossRefPubMedGoogle Scholar
  27. Nussbaum ES, Djalilian HR, Cho KH, Hall WA (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78(8):1781–1788CrossRefPubMedGoogle Scholar
  28. Orringer DA, Golby A, Jolesz F (2012) Neuronavigation in the surgical management of brain tumors: current and future trends. Expert Rev Med Devices 9(5):491–500PubMedCentralCrossRefPubMedGoogle Scholar
  29. Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS (2012) Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77(3):556–560CrossRefPubMedGoogle Scholar
  30. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, Markesbery WR, Macdonald JS, Young B (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494–500CrossRefPubMedGoogle Scholar
  31. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E, E. G. W. Group (2012) Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vii56–vii64CrossRefPubMedGoogle Scholar
  32. Pollock BE, Brown PD, Foote RL, Stafford SL, Schomberg PJ (2003) Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neurooncol 61(1):73–80CrossRefPubMedGoogle Scholar
  33. Posner JB, Chernik NL (1978) Intracranial metastases from systemic cancer. Adv Neurol 19:579–592PubMedGoogle Scholar
  34. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A (2012) Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123(2):205–222CrossRefPubMedGoogle Scholar
  35. Robinet G, Thomas P, Breton JL, Lena H, Gouva S, Dabouis G, Bennouna J, Souquet PJ, Balmes P, Thiberville L, Fournel P, Quoix E, Riou R, Rebattu P, Perol M, Paillotin D, Mornex F (2001) Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non- small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95–1. Ann Oncol 12(1):59–67CrossRefPubMedGoogle Scholar
  36. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Munoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia- Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L, P.-C Spanish Lung Cancer Group in collaboration with Groupe Francais de and T. Associazione Italiana Oncologia (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246CrossRefPubMedGoogle Scholar
  37. Samanci Y, Iplikcioglu C, Ozek E, Ozcan D, Marangozoglu B (2011) Lung carcinoma metastasis presenting as a pineal region tumor. Neurocirugia (Astur) 22(6):579–582CrossRefGoogle Scholar
  38. Sanai N, Eschbacher J, Hattendorf G, Coons SW, Preul MC, Smith KA, Nakaji P, Spetzler RF (2011) Intraoperative confocal microscopy for brain tumors: a feasibility analysis in humans. Neurosurgery 68(2 Suppl Operative):282–290; discussion 290PubMedGoogle Scholar
  39. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Janne PA (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368(25):2385–2394CrossRefPubMedGoogle Scholar
  40. Sidhu K, Cooper P, Ramani R, Schwartz M, Franssen E, Davey P (2004) Delineation of brain metastases on CT images for planning radiosurgery: concerns regarding accuracy. Br J Radiol 77(913):39–42CrossRefPubMedGoogle Scholar
  41. Sills AK (2005) Current treatment approaches to surgery for brain metastases. Neurosurgery 57(5 Suppl):S24–S32; discussion S21–24PubMedGoogle Scholar
  42. Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, Grisold W, Heimans J, Hildebrand J, Hoskin P, Kalljo M, Krauseneck P, Marosi C, Siegal T, Vecht C (2006) EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol 13(7):674–681CrossRefPubMedGoogle Scholar
  43. Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH, Burcoveanu D, Fukuoka M, Besse B, Pignon JP, N. c. g. meta-analysis of bevacizumab in advanced (2013) Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24(1):20–30CrossRefPubMedGoogle Scholar
  44. Tangjitgamol S, Levenback CF, Beller U, Kavanagh JJ (2004) Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer 14(3):399–422CrossRefPubMedGoogle Scholar
  45. Tsao M, Xu W, Sahgal A (2012) A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 118(9):2486–2493CrossRefPubMedGoogle Scholar
  46. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, Tans JT, Lambooij N, Metsaars JA, Wattendorff AR et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 33(6):583–590CrossRefPubMedGoogle Scholar
  47. Vogelbaum MA, Suh JH (2006) Resectable brain metastases. J Clin Oncol 24(8):1289–1294CrossRefPubMedGoogle Scholar
  48. Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B (2013) Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31(7):895–902PubMedCentralCrossRefPubMedGoogle Scholar
  49. Welzel G, Fleckenstein K, Schaefer J, Hermann B, Kraus-Tiefenbacher U, Mai SK, Wenz F (2008) Memory function before and after whole brain radiotherapy in patients with and without brain metastases. Int J Radiat Oncol Biol Phys 72(5):1311–1318CrossRefPubMedGoogle Scholar
  50. Yokoi K, Kamiya N, Matsuguma H, Machida S, Hirose T, Mori K, Tominaga K (1999) Detection of brain metastasis in potentially operable non- small cell lung cancer: a comparison of CT and MRI. Chest 115(3):714–719CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.Neurosurgery ClinicMinistry of Health Istanbul Education and Research HospitalIstanbulTurkey

Personalised recommendations